STRO Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio—Forward 10.03
EPS (TTM)$-16.350.0% YoY
Profit margin-154.2%HEALTHCARE
Market cap$470.8MSmall cap
Wall Street coverage
$48.31median target· current $32.80 (+47.3%)12 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 10.03
- PEG ratio
- —
- P/B
- 2.11
- P/S (TTM)
- 4.73
- EV/EBITDA
- 41.71
Profitability & growth
- ROE (TTM)
- -1810.0%
- Operating margin
- -203.9%
- Revenue growth YoY
- -16.5%
- Dividend yield
- —
- Beta
- 1.55
Last earnings
May 14, 2026 · Estimate $-3.22 · Reported $-2.94
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Sutro Biopharma
Company profileSutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. The company is headquartered in South San Francisco, California.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$470.8M
Shares outstanding$16.6M
52W high$43.85
52W low$6.74
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent